In addition to its ability to block the activation of angiogenic and tumorigenic RTKs, it has been shown that anlotinib reduces SS cellular proliferation and xenograft tumor growth through targeting of GINS1, a DNA replication complex subunit found to be highly expressed in SS and associated with poor prognosis [121]. This evidence concerns the gene GINS1 and synovial sarcoma.